Thomas Dudler

Thomas Dudler is an accomplished professional in the biopharmaceutical industry, currently serving as Director/Senior Director of Research at Omeros Corporation since July 2007. Notable achievements include leading the OMS1029 product team through a successful Phase 1 study for a MASP-2 antibody and overseeing the development of narsoplimab, a first-in-class MASP-2 antibody currently under FDA review. Experience at Omeros includes significant responsibilities across various roles, such as Associate Director and Senior Group Leader, with a focus on antibody development, clinical trial preparation, and pharmacokinetic assessments. Prior experience includes roles at ICOS Corp, the Imperial Cancer Research Fund, and the University of Washington, with a strong foundation in immunology and biochemistry, evidenced by a PhD from the University of Zurich and a Bachelor's degree from the Université de Fribourg.